Danish Electrical Stock News

Demant (CPSE:DEMANT) has reported FY 2025 second half revenue of DKK 11.7b with EPS of DKK 5.87, while trailing twelve month revenue stands at DKK 23.0b and EPS at DKK 11.21, setting the stage for a results season where profits and sales are both firmly in focus. The company has seen revenue move from DKK 11.3b in the second half of 2024 to DKK 11.7b in the second half of 2025, with half year EPS shifting from DKK 7.15 to DKK 5.87 and trailing twelve month EPS moving from DKK 13.31 to DKK...

Novo Nordisk (CPSE:NOVO B) has closed out FY 2025 with fourth quarter revenue of DKK 79.1 billion and basic EPS of DKK 6.05, against trailing twelve month revenue of DKK 309.1 billion and EPS of DKK 23.06. Over recent periods, the company has seen quarterly revenue range from DKK 74.9 billion to DKK 85.7 billion, with basic EPS moving between DKK 4.50 and DKK 6.54. This sets the backdrop for investors focused on how margins and earnings sustainability shape the story from here. See our full...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Most readers would already be aware that Roblon's (CPH:RBLN B) stock increased significantly by 19% over the past three...

Insiders who purchased Dampskibsselskabet Norden A/S ( CPH:DNORD ) shares in the past 12 months are unlikely to be...

A.P. Møller - Mærsk (CPSE:MAERSK B) has resumed routing its Gemini ME11 container service with Hapag-Lloyd through the Red Sea and Suez Canal, using naval escorts to support schedule reliability on key IMEA to Mediterranean trades. See our latest analysis for A.P. Møller - Mærsk. The decision to send Gemini ME11 back through the Red Sea comes after a busy period for A.P. Møller - Mærsk, with a DKK14.4b share buy-back program underway and new leadership appointed for the IMEA region. This has...

Netcompany Group (CPSE:NETC) has wrapped up FY 2025 with Q4 revenue of DKK 2.26b and basic EPS of DKK 3.19, alongside trailing twelve month revenue of DKK 7.89b and EPS of DKK 5.48 anchoring the full year picture. Over recent quarters, the company has seen quarterly revenue move from DKK 1.68b in Q4 2024 to DKK 1.74b in Q1 2025, DKK 1.71b in Q2, DKK 2.17b in Q3 and then DKK 2.26b in Q4. EPS has ranged from DKK 2.45 in Q4 2024 to DKK 2.58, DKK 1.18, a loss of DKK 1.44, and then DKK 3.19...

Embla Medical hf (CPSE:EMBLA) has wrapped up FY 2025 with fourth quarter revenue of US$256.7 million and basic EPS of US$0.058, on trailing twelve month revenue of US$928.7 million and EPS of US$0.196 that frame the latest print. Over recent periods the company has seen revenue move from US$224.8 million and EPS of roughly US$0.044 in Q4 2024 to US$256.7 million and EPS of US$0.058 in Q4 2025, with trailing net income rising from US$68.3 million to US$83.3 million. This sets up a story where...

Demant A/S has released its full-year 2025 results, reporting sales of DKK 22,971 million, up from DKK 22,419 million a year earlier, while net income fell to DKK 1,545 million and basic earnings per share from continuing operations declined to DKK 11.2. The combination of higher sales but lower net income and earnings per share highlights shifting cost, margin or mix effects that may reshape how investors view Demant’s underlying earnings quality. We’ll now examine how Demant’s higher sales...

Novo Nordisk issued a sharp warning for 2026 sales and profit, citing intensifying U.S. price pressure, patent expiries, and rising competition. The company announced a large share buyback aimed at supporting market confidence during this period of expected financial pressure. CagriSema, a next generation diabetes and obesity therapy, reported superior Phase 3 results versus semaglutide, with pivotal regulatory filings underway. Novo Nordisk (CPSE:NOVO B), trading at DKK367.8, is drawing...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

ISS (CPSE:ISS) has secured a full Integrated Facility Services contract with a major life sciences and pharmaceutical client in Switzerland, valued at nearly DKK 300 million annually across four locations. See our latest analysis for ISS. The contract win comes as ISS shares trade at DKK245.2, with a 30 day share price return of 13.73% and a 90 day gain of 19.49%. The 1 year total shareholder return of 81.37% and 5 year total shareholder return of 142.04% point to strong momentum that recent...

Share reduction and what it means for UIE (CPSE:UIE) investors UIE (CPSE:UIE) is set to reduce its outstanding shares on 4 February 2026, cutting the share count by 942,690 from 32,227,690 to 31,285,000. This represents a material shift in its capital structure. See our latest analysis for UIE. At a share price of DKK382.0, UIE’s recent 90 day share price return of 20.50% and 1 year total shareholder return of 28.48%, alongside a 3 year total shareholder return of 144.50% and 5 year total...

Netcompany Group A/S has reported its full-year 2025 results, with sales rising to DKK 7,891.7 million while net income decreased to DKK 256.9 million, leading to lower basic and diluted earnings per share from continuing operations. An interesting contrast for investors is that these earnings were released just after the company completed a DKK 500 million share buyback programme aimed at adjusting its capital structure and supporting share-based incentives. We will now consider how...

H. Lundbeck A/S recently presented six-month real-world data from its 12-month INFUSE study at the 2026 Headache Cooperative of the Pacific Conference in Ojai, California, highlighting outcomes for adults with migraine treated with Vyepti (eptinezumab) after prior preventive anti-CGRP failures. The data showed meaningful improvements in multiple patient-reported outcomes, including an average 6.3 additional "good days" per month, reinforcing the clinical relevance of switching to intravenous...

Genmab (CPSE:GMAB) is back in focus after reporting that worldwide net trade sales of DARZALEX, as disclosed by Johnson & Johnson, reached US$14.351b in 2025. This figure feeds directly into Genmab’s royalty income. See our latest analysis for Genmab. Genmab’s DARZALEX update lands after a strong run in the shares, with a 10.67% 90 day share price return and a 49.98% 1 year total shareholder return. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent...

Jyske Bank has completed its share buyback programme announced in February 2025, repurchasing 5,398,229 shares, or 8.97% of its share capital, for DKK 2,249.99 million by 30 January 2026. Following the programme, Jyske Bank holds 3,309,528 treasury shares, equal to 5.38% of its share capital, underlining management’s clear capital allocation priorities. With this substantial buyback now finished, we’ll explore how such active capital management shapes Jyske Bank’s investment narrative and...

Ambu (CPSE:AMBU B) is back in focus after CEO Britt Meelby Jensen joined a Danish delegation to China and presented a Chinese made endoscope, highlighting a potential shift in the company’s geographic risk profile. See our latest analysis for Ambu. The new China focus comes after a tough run for shareholders, with the share price at DKK84.7 and a 1-year total shareholder return decline of 36%, extending a 5-year total shareholder return drop of 74%. This suggests momentum has been fading...

Danske Bank has completed its DKK 5,000,000,000 share buy-back programme, repurchasing 19,179,623 shares that are expected to be cancelled subject to shareholder approval at the March 26, 2026 annual general meeting. This move underscores a capital position that allows meaningful cash returns to investors and signals management’s confidence in the bank’s current trajectory. We’ll now examine how the completed DKK 5,000,000,000 buy-back and planned share cancellation shape Danske Bank’s...

ALK-Abelló (CPSE:ALK B) is back in focus after regulators in Europe issued a positive opinion on extending EURneffy marketing authorisation to include a 1 mg nasal adrenaline spray for younger children. See our latest analysis for ALK-Abelló. The CHMP opinion appears to have been a fresh catalyst, with ALK-Abelló’s 1-day share price return of 2.12% standing out against a 30-day share price return decline of 6.44%. Its 1-year total shareholder return of 34.35% and 3-year total shareholder...

Novo Nordisk and Aspect Biosystems have moved into a new phase of their diabetes cell-therapy partnership, with Aspect acquiring key stem cell and hypoimmune engineering rights, plus integrated Novo Nordisk R&D and manufacturing capabilities, while Novo Nordisk keeps options to expand its role and earn milestones and royalties on future products. By handing operational leadership of next-generation cell therapies to Aspect while retaining financial and later-stage participation rights, Novo...

Event driven spotlight on Carlsberg stock Carlsberg (CPSE:CARL B) has agreed to sell its 50% stake in Tibet based Lhasa Brewery to Tibet Development, exiting a joint venture that faced management disputes and weaker unit level financial performance. The deal, completing just before Carlsberg’s annual results, removes a contested asset from the portfolio and gives investors fresh context for assessing the group’s earnings profile and capital allocation priorities. See our latest analysis for...

NKT announced that it has signed final contracts under its framework agreement with SSEN Transmission to deliver 525 kV HVDC on- and offshore power cable systems for the Western Isles and Spittal to Peterhead links in Scotland, adding about €2.00 billion to its high-voltage order backlog. Beyond expanding NKT’s backlog, the projects highlight the company’s role in enabling large-scale grid reinforcement for Great Britain’s electricity transmission network. Next, we’ll examine how securing...